PS-OCT: a promising new diagnostic tool for RPE diseases

Article

Polarisation-sensitive optical coherence tomography (PS-OCT) is a promising new tool for diagnosis, disease follow-up and the evaluation of new treatment strategies in disease affecting the retinal pigment epithelium .

Polarization-sensitive optical coherence tomography (PS-OCT) is a promising new tool for diagnosis, disease follow-up and the evaluation of new treatment strategies in disease affecting the retinal pigment epithelium (RPE), according to a study published in the February issue of the British Journal of Ophthalmology.

Stephan Michels and colleagues from the University of Vienna, the Medical University of Vienna, Austria, University Hospital Zurich, Switzerland and Moorfields Eye Hospital, London, UK evaluated pathological changes of retinal pigment epithelium using PS-OCT in 44 eyes (22 patients).

The RPE scrambles the polarization state of backscattered light (i.e. acts as a depolarizing layer), while the polarization state of transmitted light is maintained. In patients with RPE pathologies, irregularity, elevation, thickening or absence of the RPE is readily visualized by exploiting the depolarization information. Polarization scrambling in the sensory retina can be found in cases of advanced dry macular degeneration. Sclera and fibrosis show characteristic birefringence in PS-OCT.

The authors of this study believe that PS-OCT allows tissue identification based on polarization scrambling and birefringence, thus providing additional information on RPE pathologies.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Andreas Pollreisz, MD, discusses widefield OCT-A and fluorescence angiography at the 2025 European Society of Retina Specialists EURETINA meeting
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
© 2025 MJH Life Sciences

All rights reserved.